• Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

      Krebs, Matthew G; Sloane, Robert; Priest, Lynsey; Lancashire, Lee J; Hou, Jian-Mei; Greystoke, Alastair; Ward, Timothy H; Ferraldeschi, Roberta; Hughes, Andrew; Clack, Glen; et al. (2011-04-20)
      Lung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy.
    • Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.

      Evans, D Gareth R; Lalloo, Fiona; Ashcroft, Linda; Shenton, Andrew; Clancy, Tara; Baildam, Andrew D; Brain, Anne; Hopwood, Penelope; Howell, Anthony; Regional Genetic Service, The University of Manchester, St.Mary's Hospital, Manchester, United Kingdom. Gareth.evans@cmft.nhs.uk (2009-08)
      PURPOSE: The uptake of risk-reducing surgery in women at increased risk of breast and ovarian cancer is highly variable between countries and centers within countries. We have investigated the rate, timing, and age of uptake of surgery in the northwest of England to report the results after up to 7 years in a Regional Genetics center. METHODS: Uptake was documented in 211 known unaffected BRCA1/2 mutation carriers from 509 families and in 3,515 women at >25% lifetime risk of breast cancer without known mutations. RESULTS: Of the 211 mutation carriers, 40% opted for bilateral risk-reducing mastectomy (BRRM) and 45% underwent bilateral risk-reducing salpingo-oophorectomy (BRRSPO). Uptake of BRRM was significantly related to lifetime risk and age but continued over several years. In women not known to carry a BRCA mutation, 6.4% of women at 40% to 45% lifetime risk, 2.5% of women at 33% to 39% lifetime risk, and 1.8% of women at 25% to 32% lifetime risk underwent BRRM (P < 0.005). BRRSPO uptake was greater in BRCA1 (52%) than BRCA2 (28%) carriers but in both groups tended to occur within the first 2 years after gene test (except in the youngest age group) and in women between the ages of 35 and 45. CONCLUSION: To truly assess the uptake of risk-reducing surgery, longer-term follow-up is necessary particularly in younger women who are likely to delay BRRSPO. Careful risk counseling does seem to influence women's decisions for surgery, although the effect is not immediate.